I have rheumatoid arthritis — I'm going to start the monoclonal antibody infliximab — Could it cause anaphylaxis?
To clearly understand the clinical aspects involved in Monoclonal Antibody This is an essential step for those seeking diagnostic certainty, lasting symptom relief, and prevention of complications. In the daily practice of Allergology and Clinical Immunology, questions related to... "I have rheumatoid arthritis — I'm going to start the monoclonal antibody infliximab — Could it cause anaphylaxis?" Allergy-free conditions are common among patients and their families. The goal of this page in the Brazil Allergy-Free Encyclopedia is to present a complete, accessible, and evidence-based medical analysis, detailing causes, immunological mechanisms, and safe practices.
✔ Medical content reviewed and validated by the founding clinical staff of the Brazil Without Allergies Project
Dr. Marcello Bossois (CRM-RJ 52.73214-1) · Dr. Patricia Schlinkert (CRM/RJ 5274541-3) — more than 30 years of history in Allergy and Immunology, with units in Rio de Janeiro, São Paulo and Paraná. Last reviewed: November 2026.
Clinical Analysis and Medical Guidance on Monoclonal Antibodies
Question: “I have rheumatoid arthritis, and my doctor is considering starting me on the monoclonal antibody infliximab. I'm afraid because I've seen that it can cause anaphylactic shock, and I've had that problem before after eating shrimp. Do you have any experience with the safety of this medication?”
You monoclonal antibodies They can, indeed, cause anaphylaxis in some cases. infliximab It's an anti-tumor necrosis factor (TNF), a pro-inflammatory substance produced in abundance in rheumatoid arthritis.
One of the mechanisms is as follows: infliximab binds to the antigen and forms immune complexesThese immune complexes, containing IgG class antibodies, can bind to receptors of mast cell, activating it and leading to the release of histamine and anaphylaxis.
It's difficult to know beforehand if there will be a reaction. Therefore, talk to your specialist doctor and always administer the injections under medical supervision. supervision Proper care is essential, with all necessary medication to treat a potential anaphylactic crisis readily available—the same applies to other biologics, such as omalizumab (anti-IgE). With these precautions, treatment is quite safe, and complications can be controlled.
Developments in Evidence-Based Medicine: Pharmacology of Immunobiologics and Precision Medicine
In Evidence-Based Medicine, the indication of immunobiological agents (monoclonal antibodies and receptor fusion proteins) It is based on the patient's inflammatory endotyping. Selective blocking of molecular targets — such as the neutralization of free IgE by omalizumab (in severe allergic asthma and chronic spontaneous urticaria refractory to quadrupled-dose H1 antihistamines), the dual inhibition of IL-4 and IL-13 interleukin signaling by dupilumab (In moderate to severe atopic dermatitis, eosinophilic/Th2 asthma, and chronic rhinosinusitis with nasal polyposis), the blockade of the TSLP epithelial alarm by tezepelumab or blocking the IL-5/IL-5R pathway — allows control of the inflammatory cascade at its cellular origin, reducing exacerbations and sparing the patient from the adverse metabolic, endocrine, and cardiovascular effects of prolonged systemic corticosteroid use.
💎 Diamond Plan — Eating safely and without fear of adverse reactions starts with an accurate diagnosis. Speak with an Allergy and Immunology specialist via teleconsultation, from anywhere in Brazil. Schedule a teleconsultation →
Note: Subject to prior medical evaluation (in person or via telemetry/telemedicine). Immunotherapy uses allergen-specific vaccines, which requires a prescription from the attending physician and must be administered under direct medical supervision.
Precision Medicine: How Monoclonal Antibodies and Immunobiologics Work
Selective Blockade of Cytokines (IL-4, IL-5, IL-13, TSLP) and Immunoglobulin E
Monoclonal antibodies (immunobiologics) have revolutionized the management of severe allergic and immune-mediated diseases that do not achieve full control with conventional therapies. Unlike systemic corticosteroids and classic immunosuppressants—which broadly depress immunity and generate metabolic toxicity—immunobiologics act as highly precise molecular keys, neutralizing specific targets of the inflammatory cascade: such as circulating free IgE (omalizumab), the IL-4 and IL-13 receptor (dupilumab), the eosinophilic pathway of IL-5 (mepolizumab and benralizumab), or the epithelial alarmin TSLP (tezepelumab).
Indications Criteria, Allergy Phenotyping, and Associated Therapies
Before prescribing highly complex biological therapy, the specialist reviews medication adherence, environmental factors, and test results. allergy testIn various clinical profiles, associating baseline control with protocols of allergy vaccine and to rhinitis treatment It enhances immune stability and reduces respiratory and skin exacerbations.
IgE-Mediated Allergy, Mixed Allergy, and Difference from Enzyme Intolerances
The immune system associated with the gastrointestinal mucosa normally functions by maintaining oral tolerance to thousands of dietary proteins. When this immune barrier is broken—influenced by genetic predisposition, dysbiosis of the intestinal microbiota, or immaturity of secretory IgA in childhood—intact protein fractions sensitize mast cells and basophils. Therefore, a single positive blood test reflects only biological sensitization and should always be correlated with the clinical history and, when necessary, with a supervised oral food challenge in a medical setting.
Immediate Reactions, Delayed Drug Reactions, and Risks of Self-Medication
Drug hypersensitivity reactions encompass distinct immunological and pharmacological mechanisms: from immediate reactions (up to one to six hours after dosing, manifested by urticaria, labial or palpebral angioedema, bronchospasm, and anaphylaxis, common with COX-1 inhibitor analgesics and beta-lactams) to delayed drug eruptions mediated by T cells, such as maculopapular rashes and DRESS syndrome — a systemic condition that arises weeks after the start of anticonvulsants, sulfones, or allopurinol, presenting with fever, lymphadenomegaly, eosinophilia, and the need for immediate discontinuation under hospital supervision.
Diamond Plan: Specialized Allergy Treatment Wherever You Are
We know that, for many families, allergy treatment faces two concrete obstacles: high cost of allergy vaccines and the distance to a specialized centerThe Diamond Plan It was created precisely to remove these barriers, combining teleconsultation with specialists and easy access to immunotherapy throughout the country. Eating safely and without fear of reactions starts with an accurate diagnosis.
Why do patients across Brazil choose the Diamond Plan?
- Teleconsultation with a specialist In Allergy and Immunology, without queues and without long commutes — ideal for those who live far from large cities.
- easy access to Immunotherapy (including allergy vaccines and immunostimulants) — indicated for the treatment of allergic rhinitis, asthma, bronchitis, atopic dermatitis, insect/mosquito bite allergy (prurigo strophulus), recurrent candidiasis, and for increasing immunity in selected patients — capable of modifying the natural course of allergic disease, always through consultation and individualized prescription.
- A more accessible route For those facing the high cost of allergy vaccines, this plan offers support for continuity of treatment.
- Continuous monitoring based on clinical evolution, with adjustments to treatment throughout the entire therapeutic cycle.
- National coverage, backed by a consolidated physical network and a founding clinical team with over three decades of experience.
More than 30 years caring for people with allergies.
Founded and run by Dr. Marcello Bossois (CRM-RJ 52.73214-1) and by Dr. Patrícia Schlinkert (CRM/RJ 5274541-3)The Brazil Without Allergies Project adds... more than 30 years of history and more than 450,000 free services, with physical presence at Rio de Janeiro, São Paulo and Paraná, one mobile clinic bus that brings testing and consultations to communities with limited access to specialized care and a platform of telemedicine which connects patients from all states to the same standard of care.
START TODAY
Your expert consultation is just a click away.
I want to join the Diamond Plan.Schedule a teleconsultation
Official telemedicine environment: brasilsemalergia.online
Do you prefer to be served in person?
Our clinical units They conduct consultations, allergy tests, and immunotherapy follow-up with doctors in person:
- Rio de Janeiro: Realengo (West Zone), North Zone, Duke of Caxias, Xerém, New Iguaçu, Itaguaí, Niterói, Iguaba Grande and Saint Peter of the Village (Lakes Region).
- São Paulo: Campo Limpo (South Zone).
- Paraná: Curitiba.
Schedule your in-person appointment. Or check the mobile bus schedule through the customer service center on WhatsApp. (21) 99954-5632.
The indication for immunotherapy, and for any treatment, depends on an individual medical evaluation. This content is for informational purposes only and does not replace consultation with a specialist.
Note: Subject to prior medical evaluation (in person or via telemetry/telemedicine). Immunotherapy uses allergen-specific vaccines, which requires a prescription from the attending physician and must be administered under direct medical supervision.
Conclusion and Summary of Guidelines
In summary, the appropriate approach to Monoclonal Antibody It requires a clear understanding of the immunological mechanisms involved, precise etiological diagnosis, and individualized medical follow-up. Avoiding self-medication and investigating the root cause of symptoms—relying on specialized resources and reliable guidance such as specialized allergy and immunology care when clinically relevant—is the safest way to control flare-ups, prevent complications, and ensure sustainable quality of life.
Scientific references and authoritative sources
The guidelines on this page follow the guidelines and literature of leading international Allergy and Immunology institutions. For further information:




